PET scanning and prognosis in Hodgkinʼs lymphoma
- 1 September 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 20 (5) , 509-516
Abstract
Risk-adapted treatment strategies are currently under investigation in the management of patients with lymphoma. This review presents the latest evidence for the use of early interim [(18)F]-fluorodeoxyglucose-positron emission tomography for risk-adapted treatment in Hodgkin's lymphoma. In recent years, PET after two cycles of ABVD (adriamycin, bleomycin, vincristin, and dexamethasone) was shown to be the only independent prognostic factor for the prediction of relapse in Hodgkin's lymphoma and to have at least the same prognostic accuracy as end-of-treatment PET. A high prognostic value of PET was reported even earlier, before the second cycle of chemotherapy. The earlier PET becomes negative, the more chemosensitive the disease, which may offer opportunities toward the limitation of the therapy. However, more false-positive lesions occur at earlier time points, and preliminary results indicate that accuracy of PET results differs after BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and immunotherapy. [(18)F]-Fluorodeoxyglucose-positron emission tomography after two cycles of ABVD is now recognized as the single most important factor in defining disease-specific outcome and is highly promising for investigation of response-adapted treatment strategies. It is now recognized that the optimal time point of PET for response evaluation is crucial and dependent on the administered treatment. Standardization of PET-response is essential and should be adapted to time-dependent and therapy-dependent changes.Keywords
This publication has 16 references indexed in Scilit:
- Is [18F]fluorodeoxyglucose Positron Emission Tomography the Ultimate Tool for Response and Prognosis Assessment?Hematology/Oncology Clinics of North America, 2007
- Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish StudyJournal of Clinical Oncology, 2007
- Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chainsHaematologica, 2007
- PET and PET/CT for response evaluation in lymphoma: Current practice and developmentsLeukemia & Lymphoma, 2007
- FDG‐PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin diseaseCancer, 2006
- Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin’s Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2005
- Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphomaAnnals of Oncology, 2005
- Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 2003
- Comparison of prognostic models in patients with advanced Hodgkin diseaseCancer, 2001
- A Prognostic Score for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 1998